Ferric carboxymaltose for the treatment of iron-deficient heart failure patients: a systematic review and meta-analysis.

ABSTRACT:

Aims

Intravenous ferric carboxymaltose (FCM) has been shown to improve functional capacity and quality of life in iron deficient heart failure patients. However, FCM's effect on hospitalizations and mortality remains unclear as previous randomized controlled trials (RCTs) and their meta-analyses have been underpowered to detect significant differences. We sought to conduct an updated meta-analysis using recently published RCT data.

Methods and results

Online databases were searched from inception until November 2020 for RCTs evaluating the effects of FCM on clinical outcomes in iron-deficient heart failure patients. Outcomes of interest included heart failure hospitalizations, all-cause mortality, and cardiovascular mortality. Meta-analysis was performed using a fixed-effect

SUBMITTER: Khan MS 

PROVIDER: S-EPMC7754952 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature